Evidence map›Paper›PMID 36469609›Full record

ArticleCurrent protocols2022

Formulation and Evaluation of Polymer-Based Nanoparticles for Intravitreal Gene-Delivery Applications.

Daiheon Lee, Gijung Kwak, Thomas V Johnson, Jung Soo Suk

Open access · greenAbstract read
In one paragraph

Article in Current protocols, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 88% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Daiheon LeeDepartment of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Gijung KwakDepartment of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Thomas V JohnsonDepartment of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Jung Soo SukDepartment of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Johns Hopkins University · US

Funding

Wilmer Core Grant for Vision ResearchP30EY001765 · NEI · JOHNS HOPKINS UNIVERSITY · PI Ji Yi · 1985 to 2026
$22.1M
Localized SDF-1 mRNA nanoparticle delivery for treating erectile dysfunction.R01DK132425 · NIDDK · UNIVERSITY OF MARYLAND BALTIMORE · PI HANNAN, JOHANNA LUCY, SUK, JUNG SOO · 2022 to 2025
$2.0M
Transplantation of human stem cell-derived neurons for retinal ganglion cell replacement and optic nerve regeneration.K08EY031801 · NEI · JOHNS HOPKINS UNIVERSITY · PI JOHNSON, THOMAS VINCENT · 2020 to 2024
$945k
NEI NIH HHS K08 EY031801NEI NIH HHS P30 EY001765NIDDK NIH HHS R01 DK132425
6 · The paper itself

Abstract

The advent of the first-ever retinal gene therapy product, involving subretinal administration of a virus-based gene delivery platform, has garnered hope that this state-of-the-art therapeutic modality may benefit a broad spectrum of patients with diverse retinal disorders. On the other hand, clinical studies have revealed limitations of the applied delivery strategy that may restrict its universal use. To this end, intravitreal administration of synthetic gene-delivery platforms, such as polymer-based nanoparticles (PNPs), has emerged as an attractive alternative to the current mainstay. To achieve success, however, it is imperative that synthetic platforms overcome key biological barriers in human eyes encountered following intravitreal administration, including the vitreous gel and inner limiting membrane (ILM). Here, we introduce a series of experiments, from the fabrication of PNPs to a comprehensive evaluation in relevant experimental models, to determine whether PNPs overcome these barriers and efficiently deliver therapeutic gene payloads to retinal cells. We conclude the article by discussing a few important considerations for successful implementation of the strategy. © 2022 Wiley Periodicals LLC. Basic Protocol 1: Preparation and characterization of PNPs Basic Protocol 2: Evaluation of in vitro transfection efficacy Basic Protocol 3: Evaluation of PNP diffusion in vitreous gel Basic Protocol 4: Ex vivo assessment of PNP penetration within vitreoretinal explant culture Basic Protocol 5: Assessment of in vivo transgene expression mediated by intravitreally administered PNPs.

Indexed as

NanoparticlesPolymersGenetic TherapyGene Transfer TechniquesHumansRetinaPolymersinner limiting membraneintravitreal administrationpolymeric nanoparticleretinal gene therapyvitreous gel

Identifiers

PMID36469609
PMCPMC9731353
OpenAlexW4310733197

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.